Tilray brings medical cannabis products to UK

Global cannabis producer, Tilray has announced it will begin to import and distribute medical cannabis products in the UK next month.

A new agreement announced this week will allow doctors and patients to access Tilray‘s pharmaceutical-grade medical cannabis products in the UK.

The firm has reached an agreement with UK distributor, Grow Pharma, to provide locally maintained cannabis medicines for patients with a prescription.

The GMP-certified products are expected to be available by March 2021.

Tilray’s chief executive officer said the move was a step towards improving access to cannabis based medicines in the UK.

“This partnership with Grow Pharma provides patients in need access to a sustained supply of GMP-certified, high-quality medical cannabis and is an important step in improving access in the UK,” he commented.

“Tilray will continue to advocate for reasonable patient access to medical cannabis in Europe and countries around the world.”

Sascha Mielcarek, managing director of Tilray Europe, added: “As demand continues to ramp up in the UK, Tilray is well-positioned to be a leading supplier of medical cannabis products. Regulations are progressing as more and more countries across Europe are recognising the benefits of medical cannabis and its potential to improve patients’ quality of life.

“We’re pleased to reaffirm our commitment to delivering medical cannabis to patients in the UK and look forward to offering a variety of GMP-certified, pharmaceutical-grade products in the coming months.”

Grow Pharma announced earlier this month that it has trialled the UK’s first extraction of a cannabis based medicine in a licensed facility, since GW Pharmaceuticals and Epidiolex.

CEO, Pierre van Weperen said: “We’re proud to join forces with Tilray and provide patients in need with a secure and sustainable supply of the highest-quality medical cannabis products in the UK.”